In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on EDAP TMS (NASDAQ: EDAP), with a price target of $6.50. The company’s shares closed yesterday at $2.43.
Ramakanth wrote:
“We have adjusted our financial model to reflect the reported 1Q18 financial results. For 2018, we project revenues of approximately €39.0M and a net loss of €0.01 per share. The company reported €18.1M in cash, cash equivalents and short- term investments as of March 31, which we believe is sufficient to fund operations for the foreseeable future.”
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 6.4% and a 41.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Eleven Biotherapeutics.
EDAP TMS has an analyst consensus of Moderate Buy, with a price target consensus of $6.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.85 and a one-year low of $2.07. Currently, EDAP TMS has an average volume of 42.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
EDAP TMS SA develops, produces and markets minimally invasive medical devices for urological diseases. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects.
